Track market-moving stories before they get noisy

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Koh Boon Hwee, independent chair of the company's board of directors, retired from the board effective Sept. 4, 2026, following more than two decades of service as a director. Koh joined Agilent's board in 2003 and served as independent chair from 2017 until his retirement.He chaired the board's Executive Committee and Nominating and Corporate Governance Committee. Koh brought extensive international l.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent's ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency.

Did you analyze how Agilent Technologies (A - Free Report) fared in its international operations for the quarter ending July 2026? Given the widespread global presence of this scientific instrument maker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.

The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.

Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.

Upon examining A's recent quarterly performance, we noticed several interesting patterns in the revenue generated from its international segments, which are commonly analyzed and observed by Wall Street experts.

The company's total revenue for the quarter amounted to $1.88 billion, marking an increase of 8.1% from the year-ago quarter. We will next turn our attention to dissecting A's international revenue to get a clearer picture of how significant its operations are outside its main base.

A Closer Look at A's Revenue Streams AbroadOf the total revenue, $504 million came from Europe during the last fiscal quarter, accounting for 26.8%. This represented a surprise of -3.24% as analysts had expected the region to contribute $520.85 million to the total revenue. In comparison, the region contributed $518 million, or 28.2%, and $492 million, or 28.3%, to total revenue in the previous and year-ago quarters, respectively.

During the quarter, Asia Pacific contributed $613 million in revenue, making up 32.6% of the total revenue. When compared to the consensus estimate of $594.26 million, this meant a surprise of +3.15%. Looking back, Asia Pacific contributed $553 million, or 30.1%, in the previous quarter, and $563 million, or 32.4%, in the same quarter of the previous year.

Revenue Forecasts for the International MarketsWall Street analysts expect Agilent to report $1.97 billion in total revenue for the current fiscal quarter, indicating an increase of 6.1% from the year-ago quarter. Europe and Asia Pacific are expected to contribute 28.3% (translating to $559.07 million), and 32.2% ($634.79 million) to the total revenue, respectively.

For the entire year, the company's total revenue is forecasted to be $7.46 billion, which is an improvement of 7.4% from the previous year. The revenue contributions from different regions are expected as follows: Europe will contribute 28.4% ($2.12 billion), and Asia Pacific 32% ($2.38 billion) to the total revenue.

Final ThoughtsAgilent's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.

Agilent currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

A Look at Agilent Technologies' Recent Stock Price PerformanceOver the past month, the stock has gained 11.2% versus the Zacks S&P 500 composite's 3.9% increase. The Zacks Medical sector, of which Agilent is a part, has risen 1.8% over the same period. The company's shares have increased 13.6% over the past three months compared to the S&P 500's 2.2% increase. Over the same period, the sector has risen 9.2%

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.88 billion for the third quarter ended July 31, 2026, representing growth of 8.1% reported and up 7.3% core(1) compared with the third quarter of fiscal year 2025. Third-quarter GAAP net income was $362 million, or $1.28 per share. This compares with $336 million, or $1.18 per share, in the third quarter of fiscal year 2025. Non-GAAP net income(3) was $459 million (including a $17 million net.

Agilent Technologies (A - Free Report) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +9.46%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.4 per share when it actually produced earnings of $1.49, delivering a surprise of +6.43%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Agilent, which belongs to the Zacks Medical - Products industry, posted revenues of $1.88 billion for the quarter ended July 2026, surpassing the Zacks Consensus Estimate by 2.08%. This compares to year-ago revenues of $1.74 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Agilent shares have added about 13.7% since the beginning of the year versus the S&P 500's gain of 12.2%.

What's Next for Agilent?While Agilent has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Agilent was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.71 on $1.97 billion in revenues for the coming quarter and $6.05 on $7.45 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Medtronic (MDT - Free Report) , is yet to report results for the quarter ended July 2026. The results are expected to be released on September 1.

This medical device company is expected to post quarterly earnings of $1.39 per share in its upcoming report, which represents a year-over-year change of +10.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Medtronic's revenues are expected to be $9.47 billion, up 10.4% from the year-ago quarter.

Alcoa’s Gallium Project Opens a New Door Beyond AluminumAgilent Technologies NYSE: A reported third-quarter fiscal 2026 revenue of $1.88 billion, with core revenue growth of 7.3%, exceeding the high end of its guidance range. The company said earnings per share were $1.56 excluding tariff-refund benefits, up 14% from a year earlier and $0.06 above the top of its guided range. Including a $20 million net benefit from tariff refunds, EPS was $1.62.

CEO Padraig McDonnell said the results reflected improving conditions in key markets as well as gains from the company’s Ignite Operating System, which has focused on pricing, procurement, supply-chain agility, commercial execution and operational discipline. Operating margin was 27.2% excluding the tariff-refund benefit, up 210 basis points year over year. Including the refunds, operating margin was 28.3%.

Get Agilent Technologies alerts:

Pharma, China and Applied Markets Drive Growth Gold and Bitcoin Are Rebounding—2 ETFs Give Investors a Different Kind of ExposurePharma revenue grew 12% during the quarter, led by double-digit biotech growth and mid-single-digit small-molecule growth. McDonnell said smaller and midsize biotechnology customers have begun increasing spending as funding conditions improve. Agilent’s Advanced Therapeutics division, which includes its NASD and BioVectra specialty CDMO operations, grew nearly 30%.

The company also reported more than 70% growth in GLP-1-related revenue, with contributions from both its CDMO and analytical laboratory businesses. Excluding the CDMO business, Agilent said biopharma revenue increased 9%.

3 Contrarian Trades for a Market That Looks Too HotChemicals and advanced materials grew 7%, exceeding the company’s mid-single-digit expectation. Advanced materials posted double-digit growth, supported by semiconductor-related demand for spectroscopy and vacuum tools. Environmental and forensics revenue increased 5%, while PFAS-related revenue rose 20% despite a difficult comparison period.

Diagnostics and clinical revenue grew 6%, slightly below Agilent’s expectations, but the company said underlying pathology orders rose at a double-digit rate. McDonnell said companion diagnostics grew in the mid-teens and genomics returned to high-single-digit growth. Simon May, president of the Life Sciences and Diagnostics Markets Group, said pathology order entry was strong, with a robust backlog entering the fourth quarter and continued adoption of the Dako Omnis platform.

China was a major source of upside, with revenue increasing 9% against Agilent’s prior expectation for flat growth. Growth in the region was led by double-digit pharma and food performance, as well as strength in advanced materials. McDonnell said the company saw limited benefit from government stimulus during the quarter and attributed the results to commercial execution, local capabilities and competitive wins with CXOs, pharmaceutical customers and testing laboratories.

Product Launches and Replacement Cycle Support Demand Agilent said its instrument revenue grew at a high-single-digit rate, with low-double-digit liquid chromatography growth and low-single-digit gas chromatography growth. The company recorded a book-to-bill ratio above one for the 10th consecutive quarter, indicating orders met or exceeded revenue.

McDonnell cited demand tied to liquid and gas chromatography replacement cycles, including customer upgrades to the Infinity III LC platform. He also highlighted the company’s newest product launches, including the 9500 Triple Quad ICP-MS, the 8890B and 8860B gas chromatography systems, and the Altura family of analytical columns.

The 9500 ICP-MS began shipping in late July and has already surpassed Agilent’s ramp-to-volume target, according to McDonnell. Its order funnel exceeds $60 million. Orders for the new gas chromatography systems exceeded company expectations by more than two times during their first two months of availability.

Agilent also said the number of new accounts adopting biopharma Altura columns increased 28% sequentially. The company completed its Biocare Medical acquisition in late June, and CFO Adam Elinoff said Biocare contributed $10 million in third-quarter revenue. The company expects about $23 million of Biocare revenue in the fourth quarter.

Reshoring Opportunity Begins to Produce Orders Management said pharmaceutical reshoring is beginning to create instrument and service demand. Agilent booked its initial pharma reshoring orders during the third quarter, earlier than expected, including orders from five of the world’s 10 largest pharmaceutical companies.

McDonnell reiterated the company’s estimate of a roughly $1 billion reshoring opportunity through 2030 and said Agilent expects to capture at least one-third of that opportunity. He said revenue from the trend is expected to begin building in fiscal 2027, though quarterly contributions may not be linear.

Agilent also sees opportunity from semiconductor capacity investments and AI infrastructure spending. The company said semiconductor-related demand could support advanced materials growth over the medium term, with instrument demand typically emerging 18 to 24 months after fab construction. Management noted that semiconductor manufacturing also creates longer-term PFAS testing demand.

Margins, Cash Flow and Updated Outlook Gross margin was 56.4% in the third quarter, or 54.9% excluding the net tariff-refund benefit. Elinoff said the ex-refund gross margin increased 180 basis points from the prior year due to incremental volume leverage and Ignite-related improvements.

Operating cash flow was $519 million and free cash flow was $439 million, representing a 96% conversion of non-GAAP net income. Agilent repurchased $78 million of stock and paid $72 million in dividends during the period. Following a $600 million senior-notes offering completed alongside the Biocare transaction, the company ended the quarter with net leverage of one turn.

For fiscal 2026, Agilent raised its outlook for reported revenue to $7.49 billion to $7.51 billion, representing 5.8% to 6.0% core growth. The revised midpoint is 65 basis points above its prior forecast. The company now expects full-year EPS of $6.18 to $6.21, including the third-quarter tariff-refund benefit. Excluding that benefit, it expects EPS of $6.12 to $6.15, representing 10% growth at the midpoint.

Fourth-quarter reported revenue is projected at $1.98 billion to $2.0 billion. Fourth-quarter core revenue growth is expected to be approximately 5.2% to 6.2%. Fourth-quarter EPS is forecast at $1.71 to $1.74, representing growth of 8% to 9%. The fourth-quarter outlook does not include any potential future tariff refunds. Elinoff said Agilent continues to expect $1.6 billion to $1.7 billion in operating cash flow for the full year and about $450 million in capital expenditures. He added that the company expects Ignite efficiencies to help offset inflationary pressures related to the Middle East conflict and memory-chip demand.

About Agilent Technologies (NYSE:A)Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Agilent Technologies Right Now?Before you consider Agilent Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.

While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

10.64K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in A over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Allworth Financial LP purchased a new stake in Agilent Technologies, Inc. (NYSE:A – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,420 shares of the medical research company’s stock, valued at approximately $2,712,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of A. Brighton Jones LLC increased its position in Agilent Technologies by 6.1% during the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after buying an additional 270 shares during the period. Jones Financial Companies Lllp raised its stake in Agilent Technologies by 15.9% during the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock worth $602,000 after acquiring an additional 769 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Agilent Technologies by 54.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 212 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Agilent Technologies by 16.5% in the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock valued at $625,000 after buying an additional 758 shares during the period. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Agilent Technologies during the second quarter worth $273,000.

Agilent Technologies Stock Performance Shares of A opened at $159.25 on Friday. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. The stock has a market cap of $44.98 billion, a P/E ratio of 31.98, a P/E/G ratio of 2.77 and a beta of 1.25. The business’s 50 day moving average price is $137.57 and its 200-day moving average price is $126.23. Agilent Technologies, Inc. has a 52 week low of $108.35 and a 52 week high of $160.51.

Agilent Technologies (NYSE:A – Get Free Report) last released its earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.08. The firm had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Equities research analysts anticipate that Agilent Technologies, Inc. will post 6.03 earnings per share for the current fiscal year. Wall Street Analysts Forecast Growth A has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. Royal Bank Of Canada started coverage on Agilent Technologies in a research note on Wednesday, May 27th. They set an “outperform” rating and a $153.00 price objective on the stock. Sanford C. Bernstein started coverage on Agilent Technologies in a report on Friday, June 26th. They set an “outperform” rating and a $155.00 price target on the stock. Robert W. Baird upped their price objective on Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research note on Tuesday, May 26th. Finally, Wells Fargo & Company decreased their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $160.24.

Read Our Latest Stock Analysis on A

Agilent Technologies Profile (Free Report)

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Further Reading Five stocks we like better than Agilent Technologies Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Wall Street analysts forecast that Agilent Technologies (A - Free Report) will report quarterly earnings of $1.48 per share in its upcoming release, pointing to a year-over-year increase of 8%. It is anticipated that revenues will amount to $1.84 billion, exhibiting an increase of 5.9% compared to the year-ago quarter.

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

In light of this perspective, let's dive into the average estimates of certain Agilent metrics that are commonly tracked and forecasted by Wall Street analysts.

According to the collective judgment of analysts, 'Net Revenue- Applied Markets' should come in at $336.29 million. The estimate indicates a year-over-year change of +3.8%.

Based on the collective assessment of analysts, 'Net Revenue- Agilent Crosslab Group' should arrive at $791.36 million. The estimate indicates a change of +6.4% from the prior-year quarter.

The consensus among analysts is that 'Net Revenue- Life Sciences and Diagnostics Markets Segment' will reach $712.11 million. The estimate indicates a change of +6.3% from the prior-year quarter.

View all Key Company Metrics for Agilent here>>>

Over the past month, shares of Agilent have returned +11.9% versus the Zacks S&P 500 composite's +2.8% change. Currently, A carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Advisors Capital Management LLC purchased a new position in Agilent Technologies, Inc. (NYSE:A – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 62,474 shares of the medical research company’s stock, valued at approximately $8,299,000.

Several other large investors also recently added to or reduced their stakes in A. SHP Wealth Management purchased a new stake in Agilent Technologies during the 4th quarter valued at $26,000. Core Wealth Advisors LLC bought a new stake in Agilent Technologies in the fourth quarter worth $26,000. Navalign LLC purchased a new position in Agilent Technologies during the fourth quarter worth $27,000. MV Capital Management Inc. purchased a new position in Agilent Technologies during the fourth quarter worth $28,000. Finally, Entrust Financial LLC bought a new position in Agilent Technologies during the fourth quarter valued at $31,000.

Analyst Ratings Changes A has been the subject of several analyst reports. TD Cowen raised their target price on shares of Agilent Technologies from $147.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Jefferies Financial Group started coverage on shares of Agilent Technologies in a report on Thursday, July 9th. They set a “hold” rating and a $135.00 price target on the stock. Royal Bank Of Canada started coverage on shares of Agilent Technologies in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $153.00 price objective on the stock. Bank of America raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $150.00 to $145.00 in a research note on Thursday, May 28th. Finally, Weiss Ratings raised Agilent Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $160.24.

Read Our Latest Stock Report on A Agilent Technologies Stock Up 0.7% NYSE:A opened at $156.50 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. The stock has a market capitalization of $44.20 billion, a P/E ratio of 31.43, a P/E/G ratio of 2.75 and a beta of 1.25. The company’s 50-day simple moving average is $136.98 and its 200-day simple moving average is $126.00. Agilent Technologies, Inc. has a fifty-two week low of $108.35 and a fifty-two week high of $160.27.

Agilent Technologies (NYSE:A – Get Free Report) last announced its earnings results on Wednesday, May 27th. The medical research company reported $1.49 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.08. The firm had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.80 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. On average, equities analysts anticipate that Agilent Technologies, Inc. will post 6.03 earnings per share for the current fiscal year.

Agilent Technologies Profile (Free Report)

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Read More Five stocks we like better than Agilent Technologies 3 Energy Stocks Raising Dividends as the Sector Surges 5 Reasons the S&P 500 Could Keep Rallying Through Year-End Walmart’s Post-Earnings Drop Could Be a Buying Opportunity The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

BIP Wealth LLC acquired a new stake in shares of Agilent Technologies, Inc. (NYSE: A) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,277 shares of the medical research company's stock, valued at approximately $834,000. Several other institutional investors have also

Agilent Technologies (NYSE: A - Get Free Report) and Many Bright Ideas Technologies (OTCMKTS:MBGNF - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Analyst Recommendations This is a summary

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb'.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides.

-

Simplifying label-free imaging analysis for more confident real-time cell analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions.

"By making advanced AI-powered image analysis accessible to more labs, we're enabling more consistent, reproducible insights that help accelerate discovery and translational research." — Knut Wintergerst, vice president and general manager, Agilent

Share Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows are key to efficient scientific progress. AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis.

By replacing subjective, user-influenced thresholding and manual parameter tuning with a one-click approach, the new module delivers standardized analysis across skill levels, experiments and datasets. eSight imaging AI analysis is designed to ensure confident, reliable performance across users, cell types and assay conditions, providing the robustness and accuracy essential for real-world science and users with varying levels of imaging expertise.

The new module is expected to reduce time spent on manual analysis, rework and training while supporting broader application of label-free imaging workflows, specifically within drug discovery and in high-throughput biopharma research.

"The AI analysis module for xCELLigence RTCA eSight has substantially reduced the time our users spend for image analysis," said Carole Perrot, Ph.D., core facility director at Johns Hopkins All Children's Hospital. "Its automated, consistent performance across a variety of cell types and experimental conditions has improved workflow efficiency while helping ensure reproducible results. As a shared resource supporting multiple research projects, the xCELLigence is without a doubt one of our best instruments as it simplifies complex analyses and makes advanced imaging more accessible to our users."

Knut Wintergerst, vice president and general manager of the Life Sciences and Diagnostics Markets Group at Agilent, added, "With xCELLigence RTCA eSight Software 1.5.0, Agilent is bringing the same straightforward, objective analysis customers have long valued in impedance-based measurements to label-free live cell imaging. By making advanced AI-powered image analysis accessible to more labs, we’re enabling more consistent, reproducible insights that help accelerate discovery and translational research."

By simplifying label-free imaging analysis within an integrated imaging and impedance workflow, eSight AI helps researchers reduce complexity, gain more confident biological insights and accelerate the path from experiment to interpretation.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

More News From Agilent Technologies Inc.

Back to Newsroom

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent's Life Sciences and Diagnostics Markets Group.“We are pleased to complete our acquisition of Biocare, which represents a natural and st.

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of Erasca, Inc. (NASDAQ: ERAS) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased ERAS securities between January 14, 2025 and April 26, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. Find out if you qualify to recover your per-share losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

From a closing price of $21.49 on April 24, 2026, Erasca shares collapsed to $9.90 by the close of trading on April 28, 2026. That $11.59 per-share decline, representing a 53.9% loss of value, followed two corrective disclosures that stripped away what the lawsuit maintains was artificial inflation built on misleading preclinical comparisons and undisclosed safety and intellectual property risks. The last day to move for lead plaintiff is August 10, 2026.

The April 27, 2026 Pre-Market Disclosure

Before markets opened on April 27, 2026, Erasca filed a Form 8-K disclosing that Revolution Medicines had sent a letter alleging ERAS-0015 infringes U.S. Patent No. 12,409,225 and involves trade secret misappropriation. RevMed further alleged that Erasca had made "deceptive and untrue comparative statements" about ERAS-0015 versus RMC-6236. Shares fell from $21.49 to close at $19.15 that day, a decline of approximately $2.34 per share (10.9%).

The April 27, 2026 Post-Market Disclosure

After the close on the same day, Erasca filed a second Form 8-K reporting preliminary Phase 1 clinical data. That filing disclosed a patient death classified as a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5. The filing also conceded that all comparisons between ERAS-0015 and RMC-6236 were based on cross-study analyses, were "not based on any head-to-head clinical trials," and were "inherently limited." The next morning, shares opened at $10.51 and closed at $9.90, an additional decline of $9.25 per share (48.3%) from the prior close.

Alleged Investor Damages and Loss Causation

The lawsuit maintains that throughout the class period, the market price of ERAS common stock was artificially inflated by statements promoting ERAS-0015's alleged superiority over RevMed's RMC-6236. The complaint asserts the following sequence quantifies investor harm:

Erasca repeatedly claimed ERAS-0015 achieved "comparable antitumor activity to RMC-6236 at 1/10th of the dose" and demonstrated "8-21-fold higher binding affinity to cyclophilin A"These claims were presented at major investor conferences and in SEC filings without disclosing that comparisons were cross-study analyses rather than head-to-head trialsDefendants raised approximately $258.8 million in a January 2026 stock offering while these allegedly misleading comparisons were outstandingWhen the patent infringement letter and clinical safety data were disclosed on April 27-28, 2026, the artificial inflation was removed in two stages totaling $11.59 per shareThe combined decline of 53.9% reflected the market repricing ERAS shares to account for previously concealed patent, trade secret, and clinical safety risks
"When companies fail to disclose material information, shareholders may suffer significant losses. The two-stage correction in Erasca's stock price on April 27 and 28 quantifies the gap between what investors were told about ERAS-0015 and what was actually happening." -- Joseph E. Levi, Esq.

Join the ERAS recovery action or call Joseph E. Levi, Esq. at (888) SueWallSt.

ABOUT SUEWALLST -- Over the past 20 years, SueWallSt has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, SueWallSt has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the ERAS Lawsuit

Q: How much did ERAS stock drop? A: Shares fell approximately 53.9%, a decline of $11.59 per share, after Erasca disclosed a patent infringement letter from Revolution Medicines and a patient death in Phase 1 trials on April 27-28, 2026. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.

Q: What is the ERAS lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is August 10, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: What if I already sold my ERAS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What do ERAS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What court was the ERAS class action filed in? A: The case was filed in the United States District Court for the Southern District of California, governed by the Private Securities Litigation Reform Act of 1995.

CONTACT:

SueWallSt

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, will release financial results for the second quarter of 2026 on Thursday, July 30, 2026, at approximately 7:00 AM EDT.

In addition, Tradeweb will host a conference call for investors.

WHO:

Billy Hult, CEO

Sara Furber, CFO

Ashley Serrao, Head of Treasury, FP&A and IR

WHAT:

A discussion of financial results for the second quarter of 2026 followed by a question-and-answer session

WHEN:

Thursday, July 30, 2026, at 9:30 AM EDT

A live webcast of the conference call, along with related presentation materials, will be available at https://investors.tradeweb.com/events-and-presentations.

To join the call via audio webcast, click here. To join the call via phone, click here to register in advance. Registered participants will receive an email confirmation with a unique PIN to access the conference call. An archived recording of the call will be available afterward at https://investors.tradeweb.com.

About Tradeweb Markets

Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 50 products to clients in the institutional, wholesale, retail and corporates markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves more than 3,000 clients in more than 85 countries. On average, Tradeweb facilitated more than $2.8 trillion in notional value traded per day over the past four fiscal quarters. For more information, please go to www.tradeweb.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading “Risk Factors” in the documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future events or performance and future events, our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if future events, our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of events, results or developments in future periods.

Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release.

More News From Tradeweb Markets Inc.

Alert: Claims Focus on Alleged Misrepresentations About Weakening Veterinarian Adoption and Prescription Trends That Cost ZTS Investors $23.91 Per Share Following the Final Disclosure

, /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Zoetis Inc. (NYSE: ZTS) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

Zoetis shares fell $23.91 per share on May 7, 2026, the fourth decline in a series of successive disclosures, after the Company admitted that veterinarian prescription trends, clinic patient volume, and pet owner price sensitivity had all deteriorated materially. Investors have until July 27, 2026 to seek lead plaintiff status.

How Companion Animal Prescriptions Drive Zoetis Revenue

An animal health company dependent on veterinarian-prescribed therapies cannot sustain revenue growth when the professionals who write those prescriptions lose confidence in core products. Zoetis' four flagship Companion Animal brands, which collectively generated approximately 70% of total revenue, each required veterinarian authorization before reaching a pet owner. That structure meant veterinarian willingness to prescribe was the single most important operational lever for the Company's financial performance.

The filing states that throughout 2025 and into 2026, veterinarian adoption trends for Librela were sharply weakening following the FDA's December 2024 safety warnings about seizures and deaths in treated dogs. Simultaneously, prescription volumes for Simparica Trio and dermatology products Apoquel and Cytopoint were eroding as lower-priced competitors from Elanco captured market share.

Alleged Prescription Growth Deterioration by the Numbers

Simparica franchise posted 17% U.S. growth in Q1 2025 on $260 million in revenue, but the lawsuit contends this trajectory was unsustainable as Elanco's Credelio Quattro offered tapeworm coverage Trio lacked at a lower price point Librela had reached 86% clinic penetration by May 2025, yet the action claims veterinarians were increasingly cautious about prescribing it following reports of severe neurological events Dermatology products faced direct competition from Zenrelia, which Elanco marketed as comparable or superior to Apoquel in head-to-head studies at a lower cost By Q1 2026, the Company admitted that "share loss is being amplified by a derm market with declining patient volume in the clinic" Pet owners demonstrated "increased price sensitivity," further compressing prescription volumes across all franchises The parasiticides market itself was contracting, negatively impacting compliance rates and prescription refills Clinic Volume Decline and Price Sensitivity

As detailed in the action, the operational deterioration extended beyond competitive share loss. Patient volume inside veterinary clinics declined during the period, meaning fewer dogs were even being seen for the conditions Zoetis products treated. When combined with pet owners choosing lower-cost alternatives or delaying treatment altogether, the result was a compounding effect on Zoetis' prescription-dependent revenue model that management allegedly failed to disclose until May 2026.

Calculate your potential recovery or call (212) 363-7500.

"The complaint raises serious questions about whether investors received accurate information regarding the operational health of Zoetis' prescription-driven business model, particularly as veterinarian adoption trends and clinic volumes were allegedly deteriorating throughout the Class Period." -- Joseph E. Levi, Esq.

Start your claim now or contact Joseph E. Levi, Esq. at (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report. Motions for lead plaintiff must be filed with the Court by July 27, 2026.

Frequently Asked Questions About the ZTS Lawsuit

Q: Who is eligible to join the ZTS investor lawsuit? A: Investors who purchased ZTS stock or securities between January 14, 2025 and May 6, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did ZTS stock drop? A: Shares fell approximately 21.5%, a decline of $23.91 per share, after the Company disclosed significant deterioration across its core Companion Animal business and sharply reduced full-year guidance on May 7, 2026. Investors who purchased shares during the Class Period at artificially inflated prices may be entitled to compensation.

Q: What specific misstatements does the ZTS lawsuit allege? A: The complaint alleges Zoetis made materially false or misleading statements regarding the durability of its Companion Animal growth, veterinarian adoption trends, competitive positioning, and market share across its flagship product franchises during the Class Period. When the true state was revealed, the stock price declined sharply.

Q: What do ZTS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my ZTS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the Class Period and sold at a loss may still participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP

Notice to Pension Funds, Asset Managers, and Fiduciaries Holding RGC: A $14 Billion Market Valuation Built on Zero Revenue and Twelve Employees Now Faces a DOJ Investigation, Creating Potential Fiduciary Exposure

, /PRNewswire/ -- Institutional investors holding positions in Regencell Bioscience Holdings Limited (NASDAQ: RGC) during the period October 28, 2024 through October 31, 2025 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

RGC shares traded below $0.30 for most of the Class Period before surging to $78.00 per share on June 17, 2025 before swiftly collapsing the following week, and declining a further 18.56% to only $13.56 per share on November 3, 2025 after the Company disclosed a U.S. Department of Justice subpoena. The window to apply for lead plaintiff closes on June 23, 2026.

Notice to Institutional Holders

Fund managers, pension trustees, and fiduciaries who acquired RGC ordinary shares during the Class Period face a distinct set of considerations. The lawsuit contends that Regencell's public filings contained materially misleading statements about the Company's vulnerability to market manipulation and the financial risks posed by extraordinary share price volatility that bore no relationship to underlying business performance. For institutions that held RGC based on publicly available disclosures, the alleged omissions may implicate portfolio oversight and due diligence obligations.

Contact us for institutional recovery options or call (212) 363-7500.

ERISA and Fiduciary Considerations

Institutional holders owe beneficiaries a duty of prudent oversight. Where a portfolio company's $14 billion market capitalization rests on twelve employees, no approved products, no revenue, and annual R&D spending of approximately $1 million, as alleged, the subsequent disclosure of a federal criminal investigation into share trading may trigger review obligations under ERISA and analogous fiduciary standards.

Fiduciary Obligations and Recovery Options

Institutions with the largest documented losses during the Class Period are best positioned to serve as lead plaintiff and direct litigation strategy on behalf of the entire class Lead plaintiff appointment carries no additional financial obligation; securities class actions proceed on a contingency basis with zero out-of-pocket cost to the class representative Serving as lead plaintiff allows institutional investors to select counsel, oversee settlement negotiations, and fulfill active stewardship responsibilities Fiduciaries may have an independent obligation to evaluate whether participation in this action is consistent with their duty of care to fund beneficiaries The PSLRA gives preference to movants with the largest financial interest in the relief sought, favoring institutional participants Portfolio Impact Assessment

The action alleges that Regencell's share price was artificially maintained by misleading disclosures that downplayed market manipulation risks and attributed extreme volatility solely to short-selling and third-party social media activity. As pleaded, when the DOJ subpoena was revealed on October 31, 2025, the market repriced RGC shares, producing a single-session decline of $3.09 per share. Institutions that acquired shares at prices reflecting the alleged artificial inflation bore concentrated losses.

"Institutional investors play a critical role in securities class actions. Their participation ensures rigorous oversight of the litigation process and protects the interests of all class members, including individual retail shareholders who may lack the resources to monitor complex proceedings independently." -- Joseph E. Levi, Esq.

Case Summary

The securities action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The complaint charges that Regencell and certain officers made false and misleading statements about the Company's exposure to market manipulation and the resulting risk of governmental scrutiny. The corrective disclosure came when the Company revealed it had received a DOJ subpoena and correspondence related to an investigation into trading in its ordinary shares, as well as corporate operational, financial, and accounting matters.

Contact us for institutional recovery options or contact Joseph E. Levi, Esq. at (212) 363-7500.

INSTITUTIONAL INVESTOR REPRESENTATION -- Levi & Korsinsky, LLP provides sophisticated counsel to institutional investors evaluating lead plaintiff opportunities. The firm has recovered hundreds of millions of dollars. Ranked among ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the RGC Lawsuit

Q: Who is eligible to join the RGC investor lawsuit? A: Investors who purchased RGC stock or securities between October 28, 2024 and October 31, 2025 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What is the RGC lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is June 23, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I already sold my RGC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of investor's country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP

Critical Information: $1.57 Per Share in Combined Losses Quantifies Alleged Investor Damages After Lucid Group Concealed a 29-Day Delivery Halt That Erased Significant Market Value

, /PRNewswire/ -- SueWallSt reminds purchasers of Lucid Group, Inc. (NASDAQ: LCID) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased Lucid securities between February 25, 2026 and April 13, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. Find out if you qualify to recover your per-share losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

From a closing price of $9.96, LCID shares declined to $8.80 following two corrective disclosures, a combined loss of $1.57 per share representing approximately 15.8% of shareholder value. The last day to move for lead plaintiff is July 28, 2026.

The April 3 After-Hours Disclosure

The first corrective event occurred during post-market hours on April 3, 2026. Lucid announced Q1 2026 production of 5,500 vehicles but only 3,093 deliveries, a gap of 2,407 vehicles. For the first time, the Company disclosed that Gravity SUV deliveries had been halted for 29 days because of defective second-row seat components traceable to an unauthorized supplier substitution. Reuters reported that the disruption hit hardest in February 2026, the same month management assured investors that quality problems had been "overcome." Over the following two trading sessions, shares fell $1.13, or 11.35%, to close at $8.83 on April 7, 2026.

The Alleged $1 Billion Revenue Revelation

On April 14, 2026, a Form 8-K filing disclosed preliminary Q1 revenue of $280 million to $284 million. Analysts had expected $433.8 million. The shortfall of roughly $150 million in a single quarter, combined with operating losses approaching $1 billion and a dilutive $1.05 billion capital raise, triggered an additional $0.44 per share decline, or 4.76%, to close at $8.80.

Alleged Investor Damages and Loss Causation

The lawsuit maintains that each of these disclosures removed a layer of artificial inflation from LCID's share price, inflation allegedly created by management's repeated assurances of "repeatable" operations and "structural" improvements.

The first corrective disclosure removed $1.13 per share in alleged artificial inflation when the 29-day delivery halt was revealed The second corrective disclosure removed an additional $0.44 per share when Q1 revenue came in $150 million below consensus Combined losses of $1.57 per share represent the difference between the price investors paid relying on allegedly false statements and the price that reflected disclosed reality GAAP EPS of negative $3.46 missed estimates by $0.83, further confirming the magnitude of operational deterioration Deliveries fell 41% short of the 5,237 vehicles analysts expected, a gap of 2,144 units directly tied to the concealed supplier defect TD Cowen slashed its price target from $19 to $10, citing "tougher start to the year" and execution risk Join the LCID recovery action or call Joseph E. Levi, Esq. at (888) SueWallSt.

"When companies fail to disclose material information, shareholders may suffer significant losses. In this case, the market repriced Lucid shares twice in eleven days as concealed supplier failures and their financial consequences became public, resulting in combined per-share losses of $1.57." -- Joseph E. Levi, Esq.

ABOUT SUEWALLST -- Over the past 20 years, SueWallSt has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, SueWallSt has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the LCID Lawsuit

Q: How much did LCID stock drop? A: Shares fell a combined $1.57 per share, approximately 15.8%, across two corrective disclosure events on April 3-7, 2026 and April 14, 2026. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.

Q: What specific misstatements does the LCID lawsuit allege? A: The complaint alleges Lucid made materially false or misleading statements regarding its manufacturing and delivery capabilities, specifically concealing a 29-day supplier-driven delivery halt affecting the Gravity SUV while touting "repeatable" and "structural" operational improvements. When the true state was revealed, the stock price declined sharply.

Q: What do LCID investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my LCID shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

SOURCE SueWallSt.com

The iShares Large Cap Core Active ETF is a highly concentrated, actively managed fund that has outperformed many similar ETFs since its inception in October 2023. BLCR's managers intentionally deviate from consensus, focusing on long-term earnings growth and momentum, differentiating it from passive Index funds. Fundamental analysis reveals an expensive portfolio, both relative to its peers and itself, based on its 5Y average P/E. Quality is also behind another active BlackRock ETF that I prefer.

Investors in Agilent Technologies, Inc. (A - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2026 $85 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for Agilent Technologies shares, but what is the fundamental picture for the company? Currently, Agilent Technologies is a Zacks Rank #3 (Hold) in the Medical – Products industry that ranks in the Bottom 34% of our Zacks Industry Rank. Over the last 30 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.48 per share to $1.47 in that period.

Given the way analysts feel about Agilent Technologies right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.